- ￥1500
- Absin
- abs100425
- 上海
- 2025年08月26日
- Mouse
- 见优宁维官网
企业认证
相关产品推荐更多 >
AF700 Mouse anti-Human CD61 Antibody(HIP11)【AF700 鼠抗人CD61抗体(HIP11)】- abs1841138
￥1150
Alexa Fluor® 647 Rat Anti-Mouse CD1d Antibody (S-R665)【Alexa Fluor® 647抗小鼠CD1d大鼠抗体（S - R665）】
￥550
Rabbit anti-GAD67 Polyclonal Antibody【兔抗GAD67多克隆抗体】- abs158810
￥2300
NuMA Recombinant Rabbit mAb (SDT-474-241)【NuMA重组兔单克隆抗体（SDT - 474 - 241）】
￥600
Rabbit anti-DRD1IP Polyclonal Antibody【兔抗DRD1IP多克隆抗体】
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
Mouse anti-PINK1 Monoclonal mAb(38CT20.8.5)
- 抗体英文名：
Mouse anti-PINK1 Monoclonal Antibody(38CT20.8.5)
- 靶点：
见优宁维官网
- 浓度：
见优宁维官网
- 宿主：
Mouse
- 适应物种：
见优宁维官网
- 保质期：
见优宁维官网
- 抗原来源：
见优宁维官网
- 级别：
优级
- 库存：
999
- 供应商：
Absin
- 标记物：
Unlabeled
- 克隆性：
38CT20.8.5
- 保存条件：
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
- 免疫原：
见优宁维官网
- 规格：
50uL
别名：鼠抗PINK1单克隆抗体(38CT20.8.5)见优宁维官网WB~~1:2000 IHC-P~~1:100~500 IF~~1:25Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.WBUnlabeledMouseHuman;Mouse
克隆性：38CT20.8.5
产品描述：
Purified Mouse Monoclonal Antibody (Mab)
爱必信品牌介绍：
更多详情请了解优宁维网站》》
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Monoclonal Antibody-Based Strategies in Autoimmunity and Transplantation
of therapeutic monoclonal antibodies in the fields of transplantation and autoimmunity, and discuss the salient features of antibodies presently used in the clinic-notably anti-T-cell and anticytokine antibodies. The discussion will also focus on the unique
Protocol for anti-HA antibody Western Blotting
film for ~2 mins. Notes on the primary antibody: Source : Covance/Babco Description: Crude ascites fluid monoclonal anti-HA antibody (CATLN#135032002, 11mms-101R, 0.5 ml) Handling: Aliquoted into 10ul portions in -20℃ Internal notes: labelled anti
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
